Affordability

Is Compounded Semaglutide Cheaper? Cost Comparison Explained

7 min read · Published 2026-04-17 · Sources cited to FDA / NIH / clinical trials

Yes, compounded semaglutide is typically much cheaper than brand-name Ozempic or Wegovy — often 50–80% less per month. However, compounded versions are not FDA-approved, are not required to meet the same manufacturing standards, and their legal availability changed significantly in early 2025 when the FDA resolved the semaglutide shortage.

What Do Brand-Name Semaglutide Products Actually Cost?

Without insurance, brand-name semaglutide carries a steep list price. Below are typical out-of-pocket figures based on GoodRx data as of mid-2025:

  • Ozempic (0.5 mg–2 mg, for type 2 diabetes): approximately $900–$970 per month
  • Wegovy (0.25 mg–2.4 mg, for weight management): approximately $1,300–$1,350 per month

Novo Nordisk offers a savings card that can bring Ozempic to as low as $25/month for eligible commercially insured patients. Wegovy has a similar program capping costs at $0 or $25 for qualifying patients. People on Medicare, Medicaid, or without insurance rarely qualify for these programs, leaving them exposed to full list prices.

How Much Does Compounded Semaglutide Cost?

Compounded semaglutide — typically semaglutide sodium or semaglutide base mixed at a 503A or 503B compounding pharmacy — has been widely advertised through telehealth platforms at significantly lower price points:

  • Telehealth platforms (e.g., Hims, Ro, Found): roughly $150–$350 per month, often bundling the medication with a provider visit
  • Independent 503A compounding pharmacies: roughly $100–$300 per month depending on dose and location
  • 503B outsourcing facilities: similar range, but typically requires a physician order

These prices represent potential savings of $600–$1,000 per month compared to brand-name list prices. That difference is real and meaningful for patients paying entirely out of pocket.

Important: In March 2025, the FDA officially removed semaglutide from its drug shortage list. This means most compounding pharmacies can no longer legally compound semaglutide for general use under federal law, even if some continue to do so. The FDA has stated it will take action against compounders that continue producing copies of non-shortage drugs. Always verify the current legal status with your prescriber before ordering compounded semaglutide.

How Do the Costs Compare Side by Side?

Product Type Est. Monthly Cost (No Insurance) FDA-Approved?
Ozempic (semaglutide) Brand-name ~$930–$970 Yes
Wegovy (semaglutide) Brand-name ~$1,300–$1,350 Yes
Compounded semaglutide (503A pharmacy) Compounded ~$100–$300 No
Compounded semaglutide (telehealth platform) Compounded ~$150–$350 No
Ozempic with manufacturer savings card Brand-name As low as $25 Yes

What Are the Safety and Quality Trade-Offs?

Cost is only part of the picture. The FDA has raised several specific concerns about compounded semaglutide that are worth understanding before making a decision:

  • No FDA approval: Compounded drugs skip the approval process. The FDA does not verify their potency, sterility, or bioequivalence to brand-name products. According to the FDA, it received hundreds of adverse event reports linked to compounded semaglutide between 2023 and 2025.
  • Dosing inconsistencies: Some compounded products have been found to use semaglutide salt forms (semaglutide sodium or acetate) rather than the base form used in Ozempic and Wegovy. The FDA has stated it has not evaluated whether these salt forms are safe or effective at the same doses.
  • Added ingredients: Some compounders add vitamin B12, L-carnitine, or other substances. These combinations have not been clinically tested.
  • Legal gray area post-shortage: With the shortage resolved, continued compounding of semaglutide violates federal law for most providers. Products ordered now may come from pharmacies operating outside compliance.

None of this means everyone who used compounded semaglutide was harmed — many patients reported positive experiences. But the risk profile is genuinely different from brand-name products that went through decades of clinical trials, including the landmark STEP 1 trial published in the New England Journal of Medicine (Wilding et al., 2021), which demonstrated Wegovy's efficacy and safety at the approved 2.4 mg dose.

Are There Other Ways to Lower the Cost of Brand-Name Semaglutide?

If compounded semaglutide is no longer a legal or safe option for you, several legitimate cost-reduction pathways exist:

  • Manufacturer savings programs: Novo Nordisk's NovoCare program and the Wegovy savings card can dramatically reduce costs for commercially insured patients.
  • Insurance coverage: Many employer-sponsored plans now cover Wegovy for obesity. Ozempic is more broadly covered for type 2 diabetes. Check your formulary and appeal denials with a letter of medical necessity.
  • Patient assistance programs: Novo Nordisk offers free or reduced-cost medication for uninsured patients who meet income criteria. Apply at novonordisk-us.com.
  • Switching to tirzepatide: Mounjaro and Zepbound (tirzepatide, a GIP/GLP-1 dual agonist from Eli Lilly) remain on the FDA shortage list as of mid-2025 in some doses, making compounded tirzepatide still potentially legal in certain circumstances — though this is a clinical decision to make with your prescriber.
  • Mail-order pharmacy: Using a 90-day supply through a mail-order pharmacy can reduce per-dose costs under some insurance plans.

Frequently Asked Questions

In most cases, no. The FDA removed semaglutide from its official shortage list in March 2025. Under federal law, compounding pharmacies generally cannot produce copies of commercially available, non-shortage drugs. Some pharmacies may still offer it, but doing so may violate FDA regulations. Ask your prescriber for the most current guidance.
There are no published clinical trials comparing compounded semaglutide directly to FDA-approved versions. Because compounded products are not required to demonstrate bioequivalence, there is no guarantee they deliver the same amount of active drug or produce the same clinical outcomes. Some patients reported similar results; others reported no effect or adverse events.
Semaglutide is still under patent protection by Novo Nordisk, meaning no generic version is currently available in the U.S. List prices reflect R&D costs, manufacturing, and market exclusivity. A generic semaglutide is not expected to enter the U.S. market until the mid-2030s at the earliest.
Medicare Part D covers Ozempic when prescribed for type 2 diabetes. As of 2024, Medicare Part D plans are permitted — but not required — to cover Wegovy for obesity under the Treat and Reduce Obesity Act provisions. Coverage varies by plan. Contact your Part D plan directly to confirm your specific formulary benefits.
The FDA identified risks including incorrect dosing (both under- and overdosing), use of untested salt forms of semaglutide, contamination from non-sterile compounding environments, and unlisted added ingredients. Between 2023 and 2025, the FDA received hundreds of adverse event reports associated with compounded semaglutide products, including hospitalizations.
Yes. Novo Nordisk's patient assistance program (NovoCare) offers Wegovy at no cost or reduced cost to uninsured or underinsured patients who meet income eligibility criteria. You can apply at novonordisk-us.com. Your prescriber's office can also help navigate prior authorization and appeals if you have insurance that initially denies coverage.
As of mid-2025, some tirzepatide doses remain on the FDA shortage list, which may allow certain compounding pharmacies to legally produce compounded tirzepatide in limited circumstances. However, the shortage status changes frequently. This is a rapidly evolving legal and regulatory area — confirm current status with your prescriber before pursuing this option.

Cost is a real and valid barrier to GLP-1 medications, and it makes sense to explore every available option. That said, the legal landscape around compounded semaglutide shifted significantly in early 2025, and the safety considerations are not trivial. Talk with your prescriber about manufacturer assistance programs, insurance appeals, and whether brand-name alternatives might be covered under your plan. A prescriber who specializes in obesity medicine or diabetes can often advocate more effectively on your behalf than navigating the system alone.

Sources
  • FDA. 'Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.' Updated February 2025. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
  • Novo Nordisk. Ozempic U.S. Prescribing Information. 2023.
  • Novo Nordisk. Wegovy U.S. Prescribing Information. 2023.
  • Wilding JPH, et al. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity.' NEJM. 2021;384(11):989-1002.
  • GoodRx. Ozempic and Wegovy pricing data. Accessed June 2025. https://www.goodrx.com
  • FDA. 'Compounding and the FDA: Questions and Answers.' https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  • FDA. 'FDA Updates on Semaglutide Shortage Status.' March 2025

Keep Reading

Ozempic Nausea: 10 Tips to Feel Better on Injection DayResearch & News · 6 min readTirzepatide Side Effects: What to Expect Week by WeekResearch & News · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.